Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
A phase 2 trial of Durvalumab, Ceralasertib, Olaparib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy is a phase 2 interventional study registered as NCT03334617 by AstraZeneca, with 528 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-09-13. Interventions recorded: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialA Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Shares Ceralasertib, Durvalumab, AstraZeneca, Non-small-cell lung cancer.
- TrialA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Shares Oleclumab, Durvalumab, Trastuzumab deruxtecan, AstraZeneca.
- TrialNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialA Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Shares Ceralasertib, Durvalumab, AstraZeneca.
- TrialA Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Shares Ceralasertib, AstraZeneca, Non-small-cell lung cancer.
- TrialStudy of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Shares Olaparib, Durvalumab, AstraZeneca, Small-cell lung cancer.
- TrialA Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Shares Trastuzumab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.